OPKO Health (OPK) Insider Yu Alice Lin-Tsing Buys 30,000 Shares

Yu Alice Lin-Tsing, an insider at OPK, purchased 30,000 shares of the company on June 18, 2026. This transaction wasn't part of a pre-planned trading program. Insider buying can sometimes indicate confidence in the company, though the exact price and value of the transaction weren't specified.

Other Institutional Activity in OPK

Institutional investors have been active in OPK. BlackRock, Inc. increased its holdings by 1,380,193 shares, bringing its total to 36,232,223 shares valued at approximately $41.3 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, acquiring 14,769,719 and 14,499,164 shares, respectively. Geode Capital Management, LLC also grew its stake by 240,183 shares, totaling 11,301,501 shares worth about $12.9 million. State Street Corp added 549,615 shares, raising its holdings to 9,501,377 shares valued at $10.8 million.

OPKO Health, Inc. Stock Down 14.4%

Shares of OPK traded near $1.43 on Tuesday. The company has seen varied interest from institutional investors, as indicated by recent filings. The stock's performance and institutional interest may be influenced by market conditions and company developments.

Insider Buying and Selling at OPKO Health, Inc.

In addition to Yu Alice Lin-Tsing, other insiders were active on June 18, 2026. Richard Pfenniger Jr. bought 60,000 shares, while John Paganelli, Uppaluri Subbarao, Roger Medel MD, and Prem Lachman each acquired 30,000 shares. These purchases were also not part of pre-planned trading programs.

Analysts Set New Price Targets

On March 2, 2026, Barrington Research maintained its buy rating on OPK with a price target of $1.50. Jefferies downgraded the stock to hold with a target of $1.60 on October 31, 2025. Overall, the consensus remains positive, with a majority of analysts recommending a buy.

Bottom Line

Insider buying at OPK, including Yu Alice Lin-Tsing's recent purchase, can be a sign of confidence. Institutional investors like BlackRock and Vanguard have also shown interest in the stock. Analysts largely maintain a buy rating, suggesting optimism about OPK's prospects. However, it's important to remember that 13F filings and insider transactions are backward-looking and may not reflect current positions.